U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180472) titled 'Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol' on Sept. 12.
Brief Summary: This study is designed to evaluate whether cilostazol, an antiplatelet medication, is more effective and safer than aspirin or clopidogrel in preventing recurrent strokes and slowing disease progression in patients with cerebral small vessel disease (CSVD).
Cerebral small vessel disease is a common cause of lacunar stroke, cognitive decline, and long-term disability. Currently, aspirin and clopidogrel are widely used to prevent recurrent ischemic events, but their effectiveness in CSVD remains uncer...